Skip to content

Meet Gilbert team:

Interview with Erik van der Heide

Name: 

Erik van der Heide, M.Sc.

Role title: 

Quality Assurance and Regulatory Affairs Manager

Joined Gilbert: 

2022

Office location: 

High Tech Campus Building 27, Eindhoven
Mask group (18)

Author:

Maurits Huigen, CEO

Erik van der Heide, Quality Assurance and Regulatory Affairs (QA-RA) Manager of Gilbert

Erik van der Heide has a remarkable background. He started his career as an aerospace engineer from Delft University of Technology in the Netherlands, with a major in orbital dynamics. Early on in his career Erik co-founded a company to develop research and development satellites; one satellite managed to get a place in the Guinness book of records with the longest space tether ever (31.7 km). His entrepreneurial mindset and need for challenge didn’t only show in aerospace engineering, he also started companies in renewable energy and in the medical device industry, setting up his own quality system along the way and successfully bringing his product to market. Through the latter company he got to know Maurits Huigen, who contacted Erik when a position was vacant for a QA-RA manager. So after successfully selling his medical device company, he initially joined Gilbert in 2022 as a consultant, but transferred soon into a full-time employee.

What does a QA-RA officer do on a daily basis?

As a QA-RA manager, I have the opportunity to be involved in all aspects of the organization. It is the role of the QA-RA manager to oversee all elements of quality and to make sure that the company adheres to the relevant quality standards and regulations. The medical device industry is highly regulated, and for good reason, so as a company we need to make sure that we and our suppliers comply. We are legally responsible as the manufacturer of the device, so even if we outsource part of the design or development of our liquid inhaler to partners, we need to ensure we are in control. I have learned throughout my diverse career that one shouldn’t fight quality, one should embrace it! As a QA-RA manager I can show the team through ‘real-world’, or allow me to say ‘out-of-this-world’, examples that good quality pays off. Moreover, I try to be a pro-active QA-RA manager, not only pointing out what’s wrong or not allowed, but also providing compliant alternatives and therewith contribute to solving the problem.

What are the regulatory affairs challenges for medical device companies?

When I worked in the space industry, there was a confined set of standards and regulations to follow, that in hindsight made things relatively easy. But in the medical device industry, you have to work with a diverse set of ISO and IEC standards. And when you open one standard, you get references to about three or four other standards. So it’s like unravelling a ball of yarn and as a result it quickly becomes quite complex. What makes it one level more complex, is that in our case, we are developing a medical device for respiratory drug delivery and the final drug device combination will need to also comply with the regulations governing drug device combination products. Now fortunately for Gilbert, we work with very experienced partners that also have quality and regulatory affairs departments to support and do checks and balances.

Where is Gilbert in the process?

For us there are two important regulatory milestones. First there is the ISO-13485 certification of our quality management system for the medical device industry. The second one will be the CE-marking according to the MDR, which stands for Medical Device Regulations.

 

We have recently celebrated the milestone of obtaining our ISO-13485 certification for our design and development processes, to be able to develop our technology to meet the EU medical device standards and be ready to certify our device according to the MDR. Next, we should verify the safety and performance of our device to confirm we developed the device right, and validate with users to ensure that we developed the right device. Then we have to draw up a technical file and present it to a notified body that will assess the conformity of our device. Once the notified body judges we are in compliance, the device is CE certified. Every step in this regulatory process builds up trust to future pharmaceutical partners.

What is your vision on how Pharma companies and Medical Device Manufacturers should work together?

In our case, we’re developing a Smart Precision Inhaler, that at the end of the day will be marketed and sold by a pharmaceutical company as a drug-device combination. Our device offers unique features that could enable more efficient pulmonary drug delivery. Pharma companies are developing new drugs and their development takes years before they can be marketed. We are performing feasibility studies with pharma partners and we’ve learned that in order to find an optimal drug device combination, the discussions need to start early in the development of both the device and the drug formulation. So in my view, it is never to early to reach out to us.

How is it to work at Gilbert?

I love working in technology start-ups with smart and open-minded people. Our team is very diverse from a competence perspective; we of course have engineers and scientists to develop the technology, but also commercial people to understand and develop the market. We also have key opinion leaders to identify the unmet medical needs that need addressing. So I feel that, together with our partners, we have all ingredients for our technology start-up to fulfil our mission to redefine treatment with inhaled therapies for millions of patients.

Gilbert is developing the next generation of soft mist inhalers based on a proprietary electrospray (Electro Hydrodynamic Atomization or EHDA) technology to redefine treatment for lung patients. Gilbert’s breath actuated smart precision inhaler creates a monodispersed soft mist aerosol, with a customizable droplet size enabling more precise targeting of drugs to desired regions of the lungs, which has the potential to improve the efficacy and safety of treatments. Electrospray enables gentle, efficient delivery of both small and large molecule therapies in both solution and suspension formulations.

Visit us at Gilbert | Redefining treatment for lung patients, follow us on Linkedin or contact us at info@gilbert.eu to learn if electrospray is suitable for your application.

Related posts

Let’s stay in touch!

Stay up-to-date with Gilbert’s latest news, vacancies and achievements by following us on social media.